PathWhiz ID | Pathway | Meta Data |
---|---|---|
PW002098View Pathway |
Sedoheptulose Bisphosphate BypassEscherichia coli
Sedoheptulose bisphospate bypass pathway demonstrates a series of reaction that form D-Erythrose 4-phosphate for pentose phosphate pathway and glycerone phosphate for glycolysis and pyruvate dehydrogenase pathway. D-Sedoheptulose 7-phosphate is obtained from pentose phosphate pathway, which later converted to sedoheptulose 1,7-bisphosphate via 6-phosphofructokinase-1. Fructose-bisphosphate aldolase class 2 catalyzes sedoheptulose 1,7-bisphosphate to form D-Erythrose 4-phosphate and pyruvate dehydrogenase.
|
Creator: Ana Marcu Created On: October 13, 2015 at 18:09 Last Updated: October 13, 2015 at 18:09 |
PW000466View Pathway |
disease
Segawa SyndromeHomo sapiens
Segawa syndrome is a condition in which the affected individual has a clumsy or unusual gait, and experiences involuntary muscle contractions and uncontrolled movements (dystonia). Some cases are mild, while others can be severe. The beginning signs of this condition are dystonia in the legs, and clubfeet. The cause of this condition is a mutation in the GCH1 gene. Tetrahydrobiopterin is an important compound in the production of neurotransmitters, specifically dopamine and serotonin, and the processing of quite a few amino acids, The mutation on GCH1 causes GTP cyclohydrase 1 production to be reduced or absent which causes the first three steps of tetrahydrobiopterin biosynthesis to be compromised. Dopamine is imperative in maintaining smooth muscle movements, which is why patients with Segawa syndrome experience movement problems and an unusual gait.
|
Creator: WishartLab Created On: August 29, 2013 at 08:29 Last Updated: August 29, 2013 at 08:29 |
PW121811View Pathway |
disease
Segawa SyndromeMus musculus
Segawa syndrome is a condition in which the affected individual has a clumsy or unusual gait, and experiences involuntary muscle contractions and uncontrolled movements (dystonia). Some cases are mild, while others can be severe. The beginning signs of this condition are dystonia in the legs, and clubfeet. The cause of this condition is a mutation in the GCH1 gene. Tetrahydrobiopterin is an important compound in the production of neurotransmitters, specifically dopamine and serotonin, and the processing of quite a few amino acids, The mutation on GCH1 causes GTP cyclohydrase 1 production to be reduced or absent which causes the first three steps of tetrahydrobiopterin biosynthesis to be compromised. Dopamine is imperative in maintaining smooth muscle movements, which is why patients with Segawa syndrome experience movement problems and an unusual gait.
|
Creator: Ana Marcu Created On: September 10, 2018 at 15:49 Last Updated: September 10, 2018 at 15:49 |
PW122036View Pathway |
disease
Segawa SyndromeRattus norvegicus
Segawa syndrome is a condition in which the affected individual has a clumsy or unusual gait, and experiences involuntary muscle contractions and uncontrolled movements (dystonia). Some cases are mild, while others can be severe. The beginning signs of this condition are dystonia in the legs, and clubfeet. The cause of this condition is a mutation in the GCH1 gene. Tetrahydrobiopterin is an important compound in the production of neurotransmitters, specifically dopamine and serotonin, and the processing of quite a few amino acids, The mutation on GCH1 causes GTP cyclohydrase 1 production to be reduced or absent which causes the first three steps of tetrahydrobiopterin biosynthesis to be compromised. Dopamine is imperative in maintaining smooth muscle movements, which is why patients with Segawa syndrome experience movement problems and an unusual gait.
|
Creator: Ana Marcu Created On: September 10, 2018 at 15:51 Last Updated: September 10, 2018 at 15:51 |
PW127151View Pathway |
disease
Segawa SyndromeHomo sapiens
Segawa syndrome is a condition in which the affected individual has a clumsy or unusual gait, and experiences involuntary muscle contractions and uncontrolled movements (dystonia). Some cases are mild, while others can be severe. The beginning signs of this condition are dystonia in the legs, and clubfeet. The cause of this condition is a mutation in the GCH1 gene. Tetrahydrobiopterin is an important compound in the production of neurotransmitters, specifically dopamine and serotonin, and the processing of quite a few amino acids, The mutation on GCH1 causes GTP cyclohydrase 1 production to be reduced or absent which causes the first three steps of tetrahydrobiopterin biosynthesis to be compromised. Dopamine is imperative in maintaining smooth muscle movements, which is why patients with Segawa syndrome experience movement problems and an unusual gait.
|
Creator: Ray Kruger Created On: October 25, 2022 at 15:41 Last Updated: October 25, 2022 at 15:41 |
PW128142View Pathway |
drug action
Segesterone acetate Action PathwayHomo sapiens
Segesterone acetate, also known as Annovera, is a synthetic progestin derived from 19-norprogesterone. This drug is very potent; it mediates progestational activity 100 times higher than that of progesterone. It is used as a contraceptive but also as a treatment for endometriosis in South American countries. Segesterone acetate binds selectively to progesterone receptors. This drug differs from other contraceptives because it needs to be administered parenterally since it is rapidly metabolized in the liver. Segesterone acetate is not active when taken orally, but it is proved to be an anti-ovulatory agent when given in implants, vaginal rings, or percutaneous gel. This drug acts by binding as an agonist to the progesterone receptors in the hypothalamus, this causes the level of production of Gonadotropin hormone-releasing hormone (GnRH) to increase. This lower the transcription of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) in the pituitary gland. This prevents ovulation by blocking the midcycle surge in LH, resulting in the inhibition of ovarian follicles. This drug is administered as a vaginal ring that is releasing the hormone for 21 days. The cycle of 21 days can be repeated for 13 cycles. This vaginal ring also contains ethinyl estradiol.
|
Creator: Daphnee Created On: July 24, 2023 at 11:20 Last Updated: July 24, 2023 at 11:20 |
PW146856View Pathway |
drug action
Segesterone acetate Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 19:12 Last Updated: October 07, 2023 at 19:12 |
PW128323View Pathway |
drug action
Selegiline Action PathwayHomo sapiens
Selegiline is an irreversible monoamine oxidase inhibitor (MAOIs). It is indicated for the initial treatment of Parkinson's disease and for adjunct therapy in patients that are having decreased response to levodopa or carbadopa. This molecule can also be used as a palliative treatment of Alzheimer's disease and at very high doses, for the treatment of depression. The monoamine oxidase is an enzyme that catalyzes the oxidative deamination of many amines like serotonin, norepinephrine, epinephrine, and dopamine. There are 2 isoforms of this protein: A and B. The first one is found in cells located in the periphery and breakdown serotonin, norepinephrine, epinephrine, dopamine, and tyramine. The second one, the B isoform, breakdowns phenylethylamine, norepinephrine, epinephrine, dopamine, and tyramine. This isoform is found in the extracellular tissues and mostly in the brain. The mechanism of action of the MAOIs is still not determined, it is thought that they act by increasing free serotonin and norepinephrine concentrations and/or by altering the concentrations of other amines in the CNS. MAO-A inhibition is thought to be more relevant to antidepressant activity than the inhibition caused by MAO B. Selective MAO B inhibitors have no antidepressant effects. MAO-B is involved in the nigrostriatal pathways, it accelerates the breakdown of dopamine in the cells. Selegiline binds selectively to MAO-B, this hinders the microsomal breakdown of dopamine, thereby amplifying the dopaminergic activities in the substantial nigra. At higher doses, selegiline can also binds MAO-A, enabling its application in depression treatment. This drug is administered as an oral tablet.
|
Creator: Daphnee Created On: August 21, 2023 at 08:56 Last Updated: August 21, 2023 at 08:56 |
PW145133View Pathway |
drug action
Selegiline Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 15:09 Last Updated: October 07, 2023 at 15:09 |
PW146212View Pathway |
drug action
Selenic acid Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 17:41 Last Updated: October 07, 2023 at 17:41 |